Matt Miksic
Stock Analyst at Barclays
(3.76)
# 717
Out of 4,964 analysts
295
Total ratings
60.17%
Success rate
4.27%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SENS Senseonics Holdings | Initiates: Overweight | $1.5 | $0.46 | +225.38% | 1 | Aug 27, 2025 | |
| HUMA Humacyte | Initiates: Overweight | $3.5 | $1.64 | +114.07% | 1 | Aug 27, 2025 | |
| LIVN LivaNova | Maintains: Equal-Weight | $55 → $58 | $55.64 | +4.24% | 8 | Aug 21, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $266 → $300 | $336.21 | -10.77% | 9 | Aug 21, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $53 → $51 | $11.72 | +335.15% | 7 | Aug 8, 2025 | |
| BAX Baxter International | Maintains: Overweight | $41 → $36 | $24.41 | +47.48% | 22 | Aug 4, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $21 → $22 | $16.01 | +37.41% | 3 | Aug 4, 2025 | |
| INMD InMode | Maintains: Overweight | $24 → $21 | $14.90 | +40.94% | 14 | Jul 30, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $93 → $98 | $75.07 | +30.54% | 7 | Jul 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $90 → $95 | $80.83 | +17.53% | 29 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $133 | $105.30 | +26.31% | 18 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $9 → $19 | $18.97 | +0.16% | 8 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $175.52 | +0.27% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $19 → $16 | $14.54 | +10.04% | 5 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $190.81 | +26.30% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $2.75 | +336.36% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $470.44 | +34.98% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $158 → $159 | $130.61 | +21.74% | 29 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $103 | $60.87 | +69.21% | 15 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $118 → $112 | $104.75 | +6.92% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $418 → $443 | $388.81 | +13.94% | 23 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.56 | +517.98% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $91.94 | +18.56% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $79.50 | +20.75% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $68.99 | +44.95% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $141.45 | +195.51% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.00 | +75.00% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $14.24 | +370.51% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $6.46 | +7,330.34% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $14.60 | +496.09% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $5.11 | +389.72% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $7.14 | +26.05% | 1 | Dec 12, 2016 |
Senseonics Holdings
Aug 27, 2025
Initiates: Overweight
Price Target: $1.5
Current: $0.46
Upside: +225.38%
Humacyte
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.64
Upside: +114.07%
LivaNova
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $55.64
Upside: +4.24%
Insulet
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $266 → $300
Current: $336.21
Upside: -10.77%
Tandem Diabetes Care
Aug 8, 2025
Maintains: Overweight
Price Target: $53 → $51
Current: $11.72
Upside: +335.15%
Baxter International
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $24.41
Upside: +47.48%
Alphatec Holdings
Aug 4, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $16.01
Upside: +37.41%
InMode
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.90
Upside: +40.94%
DexCom
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $93 → $98
Current: $75.07
Upside: +30.54%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $90 → $95
Current: $80.83
Upside: +17.53%
Jul 24, 2025
Maintains: Overweight
Price Target: $125 → $133
Current: $105.30
Upside: +26.31%
Jul 22, 2025
Upgrades: Equal-Weight
Price Target: $9 → $19
Current: $18.97
Upside: +0.16%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $175.52
Upside: +0.27%
Jun 9, 2025
Maintains: Equal-Weight
Price Target: $19 → $16
Current: $14.54
Upside: +10.04%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $190.81
Upside: +26.30%
May 5, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $2.75
Upside: +336.36%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $470.44
Upside: +34.98%
Apr 17, 2025
Maintains: Overweight
Price Target: $158 → $159
Current: $130.61
Upside: +21.74%
Feb 24, 2025
Maintains: Overweight
Price Target: $100 → $103
Current: $60.87
Upside: +69.21%
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $104.75
Upside: +6.92%
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $388.81
Upside: +13.94%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.56
Upside: +517.98%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $91.94
Upside: +18.56%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $79.50
Upside: +20.75%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $68.99
Upside: +44.95%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $141.45
Upside: +195.51%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.00
Upside: +75.00%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $14.24
Upside: +370.51%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $6.46
Upside: +7,330.34%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $14.60
Upside: +496.09%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $5.11
Upside: +389.72%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $7.14
Upside: +26.05%